Emisphere Technologies, Inc. (EMIS) Partner Initiates Second Phase I Trial for Oral PTH Therapy for the Treatment of Postmenopausal Osteoporosis
4/15/2010 9:55:23 AM
CEDAR KNOLLS, N.J., April 15, 2010 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that Novartis Pharma AG has initiated a second Phase I trial for an oral PTH1-34 which uses Emisphere's Eligen® Technology, and is in development for the treatment of postmenopausal osteoporosis. Emisphere Technologies is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology.
comments powered by